Galmed Pharmaceuticals Secures Patent for Aramchol, Advancing NASH Combination Therapies

Galmed Pharmaceuticals Secures Patent for Aramchol, Paving the Way for Combination Therapies in NASH Treatment

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company based in Ramot-Gan, Israel, has recently been granted a new Use Patent in South Korea for its lead compound, Aramchol. This patent, which extends the existing protections already granted in regions such as the United States, Europe, and Canada, ensures that Aramchol is protected until July 2042. As a first-in-class drug candidate ready for Phase 3 trials, Aramchol has demonstrated significant efficacy in improving fibrosis in patients with advanced liver diseases, particularly non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH).

The newly granted patent specifically covers the combination therapy of Aramchol with Madrigal Pharmaceuticals' Rezdiffra (MGL-3196, resmetirom) for treating NASH/MASH. This strategic move reflects a growing trend in the biopharmaceutical industry towards combination therapies, especially as existing monotherapies show limited effectiveness in addressing the complexities of liver diseases. Galmed's CEO, Allen Baharaff, emphasizes the importance of this patent grant, noting that Aramchol's impressive safety profile and tolerability make it an ideal candidate for combination therapies, which are increasingly viewed as vital in overcoming the therapeutic challenges posed by NASH/MASH.

As commercial interest in MASH continues to grow, Galmed Pharmaceuticals is keen to advance the development of Aramchol beyond its current focus on liver diseases. The company is also exploring the compound's potential applications in oncological indications and is committed to expanding its product pipeline to target cardiometabolic conditions. The initiation of combination therapy studies for MASH is viewed as a critical step forward in developing effective treatment strategies, positioning Galmed Pharmaceuticals favorably in a competitive market that is rapidly evolving to meet the needs of patients with complex metabolic liver diseases.

In addition to its advancements with Aramchol, Galmed Pharmaceuticals remains dedicated to enhancing its research and development capabilities. The company's focus on innovative therapies underscores its commitment to addressing unmet medical needs and improving patient outcomes in the realm of liver diseases. With the recent patent grant, Galmed is well-positioned to lead in the exploration of combination therapies that could transform the treatment landscape for patients suffering from NASH and related conditions.

As the landscape of metabolic liver disease treatment continues to evolve, Galmed’s strategic initiatives and patent protections for Aramchol highlight its role as a significant player in the biopharmaceutical industry. With continued research into combination therapies, the company aims to contribute meaningful advancements to the field, ensuring that patients have access to effective and safe treatment options for complex liver diseases.